Chemotherapy for Children with Hodgkin's Disease
Author Information
Author(s): H. Ekert, T. Fok, L. Dalla-Pozza, K. Waters, P. Smith, L. White
Primary Institution: Australian and New Zealand Children's Cancer Study Group, Royal Children's Hospital, Melbourne, Australia
Hypothesis
Can a less toxic chemotherapy regimen effectively treat newly diagnosed children with Hodgkin's disease?
Conclusion
The hybrid EVAP/ABV chemotherapy regimen was effective in achieving a lasting disease-free status in 60% of patients.
Supporting Evidence
- Overall survival was 100% with a median follow-up of 37 months.
- Relapse-free survival was 79% among evaluable patients.
- 60% of patients achieved treatment failure-free survival.
Takeaway
Doctors tested a new medicine to help kids with a type of cancer called Hodgkin's disease, and it worked well for many of them without making them too sick.
Methodology
Patients were treated with a chemotherapy protocol involving EVAP and ABV regimens, followed by assessments using imaging techniques.
Potential Biases
Potential bias due to the pilot nature of the study and withdrawal of patients for various reasons.
Limitations
The study was a pilot with a small sample size and a short follow-up period.
Participant Demographics
25 children, ages 3 to 16, with a mix of male and female participants.
Want to read the original?
Access the complete publication on the publisher's website